Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Weekly News Recap #Phispers
1. (r)-9-(2-phosphonylmethoxypropyl)adenine
2. 9-(2-phosphonomethoxypropyl)adenine
3. 9-(2-phosphonylmethoxypropyl)adenine
4. 9-(2-phosphonylmethoxypropyl)adenine, (+-)-isomer
5. 9-(2-phosphonylmethoxypropyl)adenine, (r)-isomer - T357098
6. 9-(2-phosphonylmethoxypropyl)adenine, (s)-isomer
7. 9-pmpa (tenofovir)
8. Disoproxil Fumarate, Tenofovir
9. Disoproxil, Tenofovir
10. Fumarate, Tenofovir Disoproxil
11. Tenofovir Disoproxil
12. Tenofovir Disoproxil Fumarate
13. Viread
1. 147127-20-6
2. (r)-9-(2-phosphonomethoxypropyl)adenine
3. Truvada
4. (r)-pmpa
5. Tenofovir (anhydrous)
6. Pmpa Gel
7. (r)-(((1-(6-amino-9h-purin-9-yl)propan-2-yl)oxy)methyl)phosphonic Acid
8. Apropovir
9. Gs-1275
10. Anhydrous Tenofovir
11. Tenofovir Anhydrous
12. Tenofovir (anh.)
13. Chebi:63625
14. Pmp-a
15. [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic Acid
16. ({[(2r)-1-(6-amino-9h-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic Acid
17. W4hfe001u5
18. (r)-(1-(6-amino-9h-purin-9-yl)propan-2-yloxy)methylphosphonic Acid
19. 147127-20-6 (tenofovir)
20. Gs-1278
21. 9-[(r)-2-(phosphonomethoxy)propyl]adenine
22. Phosphonic Acid, P-[[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]-
23. D,l-tenofovir
24. Tenofovir Gel
25. [(1r)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methylphosphonic Acid
26. (((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phosphonic Acid
27. (r)-[[2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]phosphonic Acid
28. {[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl}phosphonic Acid
29. Gna & Tenofovir
30. Hha & Tenofovir
31. Tfv Gel
32. Gs 1275
33. Pmpa-(r)
34. Unii-w4hfe001u5
35. Tenofovir [usan:inn:ban]
36. Rac Tenofovir
37. Anh. Tenofovir
38. Viread (prodrug For Tenofovir)
39. Phosphonic Acid, (((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-
40. Phosphonic Acid, [[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]-
41. Phosphonic Acid, P-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-
42. Tenofovir- Bio-x
43. Tenofovir (viread)
44. (r)-9-(phosphonomethoxypropyl)adenine
45. Gs 1278
46. Ks-5021
47. Tenofovir [inn]
48. Tenofovir [mi]
49. 9-pmpa
50. Chembl483
51. Ec 604-571-2
52. Tenofovir [who-dd]
53. Schembl39724
54. Tenofovir Gel (gs-1278)
55. Dtxsid9040132
56. Tenofovir, >=98% (hplc)
57. Gtpl10948
58. Bcpp000049
59. Hms3264h05
60. Zinc1543475
61. Ac-760
62. Bdbm50450813
63. Mfcd00943794
64. Akos015856701
65. Akos015894941
66. Ccg-267345
67. Cs-1609
68. Db14126
69. Phosphonic Acid, ((2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-, (r)-
70. Ncgc00167535-16
71. Bt164455
72. Hy-13910
73. (r)-9-(2-phosphonoylmethoxypropyl)adenine
74. Am20090678
75. T3006
76. (r)-9-[2-(phosphonomethoxy) Propyl] Adenine
77. C17407
78. Ab01274787-01
79. Ab01274787_02
80. Ab01274787_03
81. 127t206
82. A808613
83. Q155954
84. Sr-01000883934
85. Q-201787
86. Sr-01000883934-1
87. Brd-k15891719-001-02-8
88. [(2r)-3-(6-aminopurin-9-yl)-2-methyl-propyl] Dihydrogen Phosphate
89. [[(1r)-2(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]phosphonic Acid
90. [2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methylphosphonic Acid
91. Phosphonic Acid, [[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus Nivalis Agglutinin (gna)
92. Phosphonic Acid, [[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum Hybrid Agglutinin( Hha)
| Molecular Weight | 287.21 g/mol |
|---|---|
| Molecular Formula | C9H14N5O4P |
| XLogP3 | -1.6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 287.07834094 g/mol |
| Monoisotopic Mass | 287.07834094 g/mol |
| Topological Polar Surface Area | 136 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 354 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus. To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, [tenofovir alafenamide] and [tenofovir disoproxil].
Treatment of HIV-1 infection:
- Truvada is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.
- Truvada is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.
Pre-exposure prophylaxis (PrEP):
- Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
Tenofovir has been shown to be highly effective in patients that have never had an antiretroviral therapy and it seemed to have lower toxicity than other antivirals such as [stavudine]. In phase 3 clinical trials, tenofovir presented a similar efficacy than [efavirenz] in treatment-naive HIV patients. In hepatitis B infected patients, after one year of tenofovir treatment, the viral DNA levels were undetectable.
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
Anti-HIV Agents
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)
Reverse Transcriptase Inhibitors
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)
J05AR03
Absorption
Tenofovir as the active moiety presents a very low bioavailability when orally administered. Hence, the administration of this active agent is required to be under its two prodrug forms, [tenofovir disoproxil] and [tenofovir alafenamide]. This reduced absorption is suggested to be related to the presence of two negative charges among its structure. This negative charge limits its cellular penetration, and its passive diffusion across cellular membranes and intestinal mucosa hindering its availability for oral administration. Intravenous tenofovir has been shown to produce a maximum plasma concentration of 2500 ng/ml with an AUC of 4800 ng.h/ml.
Route of Elimination
Tenofovir is eliminated in the urine by tubular secretion and glomerular filtration. The elimination of this compound is driven by the activity of the human organic anion transporters 1 and 3 and its secretion is mainly ruled by the activity of the multidrug resistance-associated protein 4.
Volume of Distribution
Accumulation of tenofovir in plasma is related to the presence of nephrotoxic effects. It is reported that tenofovir presents a volume of distribution of 0.813 L/kg.
Clearance
The clearance of tenofovir is highly dependent on the patient renal stage and hence the clearance rate in patients with renal impairment is reported to be of 134 ml/min while in patients with normal function the clearance rate can be of 210 ml/min.
Tenofovir activation is performed by a bi-phosphorylation which in order forms the biologically active compound, tenofovir biphosphate. This metabolic activation has been shown to be performed in hepG2 cells and human hepatocytes.
The reported half-life of tenofovir is of 32 hours.
Once tenofovir is activated by a bi-phosphorylation it acts as an antiviral acyclic nucleoside phosphonate. It is a potent inhibitor of the viral reverse transcriptase with an inhibitory constant of approximately 0.022 micromolar. Once activated, tenofovir acts with different mechanisms including the inhibition of viral polymerase causing chain termination and the inhibition of viral synthesis. All these activities are attained by its competition with deoxyadenosine 5'-triphosphate in the generation of new viral DNA. Once tenofovir is incorporated in the chain, it induces a chain termination which in order inhibits viral replication. The safety of tenofovir relies on its low affinity towards the cellular DNA polymerase including the mitochondrial DNA polymerase gamma.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
